
Providers
Latest News
Latest Videos

CME Content
More News

Lifileucel was granted approval for the treatment of adults with unresectable or metastatic melanoma that has been previously treated with other therapies, marking the first approval of a tumor-derived cellular therapy in a solid tumor cancer.

The study was the first of its kind to analyze social deprivation among CLL patients and observe the underlying reasons behind their clinical outcomes.

Pain screening in young patients with sickle cell disease (SCD) has demonstrated benefits for the administration of integrative health and medicine modalities for pain management.

Details from the final interim data analysis of the ADAPT+ study confirm previous findings seen with efgartigimod (Vyvgart) in generalized myasthenia gravis (gMG), the rare neuromuscular autoimmune disease.

Coverage of Tennessee Oncology's Johann Brandes, MD, on "Precision Medicine in NSCLC."

Researchers found significant associations between individual patterns and preferences for sleeping and their biological, phenotypical age.

The former NFL running back shared his story of overcoming cancer and encouraged an audience of oncologists, pharmacists, payers, and policy leaders to continue pushing to advance cancer treatment.


A recent review suggests patients diagnosed with ovarian cancer may benefit from nutritional intervention as part of disease management, but research on the topic has been limited and further investigation is warranted.


A review and meta-analysis found mirvetuximab soravtansine to have encouraging efficacy and a tolerable safety profile in patients with recurrent ovarian cancer with folate receptor alpha (FRα) expression.

A single-institution, retrospective cohort study evaluates knowledge gaps in clinical data on Black patients with melanoma.

Consolidation durvalumab led to comparable outcomes among older patients with unresectable stage III non–small cell lung cancer (NSCLC) vs a younger cohort with the same cancer; this patient population was underrepresented in the PACIFIC trial.

A national single-center observational retrospective study reveals the long-term benefits of hematopoietic stem cell transplantation in the treatment of multiple sclerosis (MS).

In this interview, Chandler Cortina, MD, MS, FSSO, FACS, Froedtert & the Medical College of Wisconsin, addresses the impact that prioritizing mental health care can have on patients as they navigate through their cancer journey.

Over the past 20 years, Medicare physician pay has plummeted by 26% when adjusted for inflation, while hospital reimbursement has surged by 70%, prompting over 100,000 doctors to abandon independent practice for hospital or corporate employment since 2019.

Camilla Levister, MS, ANP-C, CDCES, a nurse practitioner at the Icahn School of Medicine at Mount Sinai Hospital in New York, discusses how closed-loop systems benefit patients managing type 1 diabetes.

Ann LaCasce, MD, MMSc, director of the Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology and chair of the Lymphoma Research Foundation’s scientific advisory board, discussed the changing lymphoma treatment landscape and highlighted potentially game changing treatments.

The overall decline was mainly driven by decreased incidences of epithelial cancers in the ovaries, fallopian tubes, or peritoneum, as well as a decrease in the number of patients diagnosed with epithelial cancer, especially in advanced stages.

A cross-sectional comparative study demonstrated the increased prevalence of hearing impairment in children and adults with sickle cell disease (SCD) or sickle cell traits compared with healthy individuals.

A longitudinal, observational study found that the choroid plexus, a network of blood vessels in each ventricle of the brain, plays a potential role in the neurodegenerative and chronic inflammatory process experienced by patients with relapsing remitting multiple sclerosis (MS).

Naturally occurring variations in appointment frequencies do not appear to have a major impact on clinical outcomes, but they significantly affect waiting times.

Ann LaCasce, MD, MMSc, director of the Dana-Farber/Mass General Brigham fellowship in hematology/oncology and chair of the Lymphoma Research Foundation’s Scientific Advisory Board, discusses T-cell engager therapies in the diffuse large B-cell lymphoma (DLBCL) landscape.

Mark A. Socinski, MD, executive director at AdventHealth Cancer Institute, discusses the importance of lung cancer screening in eligible patients, including the need for primary care providers to ensure screening is being implemented.

A case-control study found that patients with early-onset Merkel cell carcinoma exhibited genetic variations associated with the development of their disease.


















